Evidence map›Paper›PMID 36268576›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Distinguishing Severe Acute Respiratory Syndrome Coronavirus 2 Persistence and Reinfection: A Retrospective Cohort Study.

Sarah E Turbett, Christopher H Tomkins-Tinch, Melis N Anahtar, Caitlin M Dugdale, Emily P Hyle, Erica S Shenoy, Bennett Shaw, Kenechukwu Egbuonu, Kathryn A Bowman, Kimon C Zachary and 13 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The next viral pandemic-where do we stand?Folia microbiologica · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sarah E TurbettDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-3603-8110
Christopher H Tomkins-TinchBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, USA.
Melis N AnahtarDepartment of Pathology, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Caitlin M DugdaleDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Emily P HyleDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Erica S ShenoyDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Bennett ShawDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kenechukwu EgbuonuMassachusetts Institute of Technology, Boston, Massachusetts, USA.
Kathryn A BowmanDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kimon C ZacharyDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Gordon C AdamsBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, USA.
David C HooperDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Edward T RyanDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Regina C LaRocqueDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Ingrid V BassettDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Virginia A TriantDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Katherine J SiddleBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, USA.
Eric RosenbergDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pardis C SabetiFAS Center for Systems Biology, Harvard University, Boston, Massachusetts, USA.
Stephen F SchaffnerBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, USA.
Bronwyn L MacInnisBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, Massachusetts, USA.
Jacob E LemieuxDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Richelle C CharlesDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Funding

Development and application of a new simulation model for COVID-19R01AI042006 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Anne Neilan · 1998 to 2026
$12.9M
MOLECULAR IMMUNOLOGY AND TUMOR BIOLOGYT32CA009216 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Michael Langenau · 1985 to 2026
$10.6M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
Enhancing cardiovascular risk estimation in individuals aging with HIV/HCV co-infectionR01AG062393 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI TRIANT, VIRGINIA ATHENA · 2019 to 2023
$4.5M
Optimizing Cardiovascular Risk Prediction in HIVR01HL132786 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI D'AGOSTINO, RALPH B, TRIANT, VIRGINIA ATHENA · 2017 to 2020
$3.5M
CDC HHSHoward Hughes Medical InstituteNCEZID CDC HHS U01 CK000633NCI NIH HHS T32 CA009216NHLBI NIH HHS R01 HL132786NIAID NIH HHS R01 AI042006NIAID NIH HHS T32 AI007387NIA NIH HHS R01 AG062393
6 · The paper itself

Abstract

backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection is poorly understood, partly because few studies have systematically applied genomic analysis to distinguish reinfection from persistent RNA detection related to initial infection. We aimed to evaluate the characteristics of SARS-CoV-2 reinfection and persistent RNA detection using independent genomic, clinical, and laboratory assessments.

methodsAll individuals at a large academic medical center who underwent a SARS-CoV-2 nucleic acid amplification test (NAAT) ≥45 days after an initial positive test, with both tests between 14 March and 30 December 2020, were analyzed for potential reinfection. Inclusion criteria required having ≥2 positive NAATs collected ≥45 days apart with a cycle threshold (Ct) value <35 at repeat testing. For each included subject, likelihood of reinfection was assessed by viral genomic analysis of all available specimens with a Ct value <35, structured Ct trajectory criteria, and case-by-case review by infectious diseases physicians.

resultsAmong 1569 individuals with repeat SARS-CoV-2 testing ≥45 days after an initial positive NAAT, 65 (4%) met cohort inclusion criteria. Viral genomic analysis characterized mutations present and was successful for 14/65 (22%) subjects. Six subjects had genomically supported reinfection, and 8 subjects had genomically supported persistent RNA detection. Compared to viral genomic analysis, clinical and laboratory assessments correctly distinguished reinfection from persistent RNA detection in 12/14 (86%) subjects but missed 2/6 (33%) genomically supported reinfections.

conclusionsDespite good overall concordance with viral genomic analysis, clinical and Ct value-based assessments failed to identify 33% of genomically supported reinfections. Scaling-up genomic analysis for clinical use would improve detection of SARS-CoV-2 reinfections.

Indexed as

COVID-19COVID-19 TestingHumansReinfectionRetrospective StudiesRNASARS-CoV-2RNACOVID-19persistent detectionSARS-CoV-2 reinfection

Identifiers

PMID36268576
PMCPMC9619827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.